Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.
This hormone slows the rate of how the stomach is emptied and regulates blood sugar. Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, ...
Walgreens announced it will close 1,200 stores over the next three years, with 500 closures set for fiscal year 2025, set to end in August. CEO Tim Wentworth emphasized the need to address ...
Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they have used a GLP-1 drug ...
We’ve kind of proven that pretty conclusively,” Walgreens CEO Tim Wentworth said on an earnings call this month. Walgreens and other retailers are trying to balance deterring theft with making ...
Walgreens and Cooler Screens are suing each other after the pharmacy chain tried to get out of its contract with the company that installed refrigerator doors that can display digital ads.
A new generation of obesity drugs – such as Novo Nordisk A/S’ Wegovy and Eli Lilly and Company’s Zepbound – is changing the perception of obesity as a multifaceted illness that requires ...
David Paul Morris / Bloomberg / Getty Images Walgreens Boots Alliance shares tumbled Tuesday after Department of Justice allegations that its pharmacies dispensed prescriptions with no legitimate ...
The Department of Justice (DOJ) filed a lawsuit late last week against Walgreens alleging the company and its subsidiaries unlawfully dispensed and sought reimbursement for “millions” of ...
Walgreens announced in October that it planned to close about 1,200 underperforming stores across the country in October. The pharmacy and retail company has begun implementing its plan.
Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.
Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results